Orisild (Sildenafil)

Sildenafil, the active ingredient in Orisild, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a tablet for oral use. It treats erectile dysfunction in adult males and is also indicated for pulmonary arterial hypertension. GNH USA supplies Orisild as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sildenafil acts on the phosphodiesterase type 5 pathway to improve vascular smooth‑muscle relaxation in specific disease states.

Erectile dysfunction: improves the ability to achieve and maintain an erection when sexually stimulated. Pulmonary arterial hypertension: lowers pulmonary arterial pressure and enhances exercise capacity.

Sildenafil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Facial flushing - Indigestion or dyspepsia - Nasal congestion - Visual disturbances such as blurred vision - Back or muscle pain

Serious or Rare Side Effects: - Priapism (prolonged erection lasting more than 4 hours) - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden hearing loss or tinnitus - Severe hypotension, especially with nitrate use - Myocardial infarction or stroke in high‑risk patients - Severe allergic reactions including anaphylaxis

Before prescribing Orisild, clinicians should evaluate patient‑specific risk factors and contraindications.

Medical evaluation: assess cardiovascular health and suitability for sexual activity. Nitrate therapy: avoid concurrent use due to risk of profound hypotension. Retinitis pigmentosa: contraindicated because of possible vision complications. Alcohol consumption: limit intake as it may increase the frequency of side effects. Store at room temperature: keep in the original pack, protect from moisture and heat.

Sildenafil can interact with several drug classes; understanding the severity helps guide safe co‑administration.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin) – risk of severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase sildenafil exposure. - Guanylate cyclase stimulators (e.g., riociguat) – additive vasodilatory effect.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin) – monitor blood pressure. - Antihypertensive agents – may enhance blood‑pressure‑lowering effect. - CYP3A4 inducers (e.g., rifampicin) – may reduce efficacy of sildenafil.